Activating KRAS mutations are nearly ubiquitous in pancreatic cancer occurring in more than 95% of clinical cases. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding sequences within the 3'UTRs of target mRNAs. An integral role for miRNAs in cancer pathogenesis is well established; however, the role of miRNAs in KRASmediated tumorigenesis is poorly characterized. Here it is demonstrated that expression of miR-31 is coupled to expression of oncogenic KRAS and activity of the MAPK pathway. MiR-31 is highly expressed in patient derived xenografts and a panel of pancreatic and colorectal cancer cells harboring activating KRAS mutations. The miR-31 host gene is a large non-coding RNA that correlates with miR-31 expression and enabled identification of the putative miR-31 promoter.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs typically 18-24 nucleotides in length that cause accelerated turnover and reduced translation of target messenger RNAs. MiRNAs have been implicated in the regulation of a wide range of cellular processes including differentiation, proliferation, and apoptosis (1, 2) . A large body of evidence has established an integral role for miRNAs in cancer pathogenesis highlighting the importance of identifying miRNAs that function in the primary signaling pathways that regulate tumorigenesis. For example, the miR-17-92 cluster is directly induced by the MYC transcription factor and is able to promote cellular proliferation, survival, and tumor angiogenesis (3) . miR-34 family members are directly regulated by p53 and activate cell-cycle checkpoints and apoptosis (4) . The tumor suppressive miR-143/145 cluster is downregulated by oncogenic KRAS in pancreatic cancer and has been shown to abrogate tumorigenesis both in vitro and in vivo (5) . Although both RAS signaling and miRNA activities can profoundly influence cancer cell behavior, the role of miRNAs in RAS-mediated phenotypes is still poorly defined.
Pancreatic cancer is a deadly and highly metastatic disease with a 5 year survival rate of less than 5%. Metastasis is the leading cause of cancer-associated death, with the majority of patients having locally advanced or distant metastatic disease at diagnosis rendering their cancers inoperable. Activating mutations in the KRAS proto-oncogene are nearly ubiquitous in pancreatic ductal adenocarcinoma (PDAC) and are found in 90-95% of cases (6) . The KRAS gene mutation principally encountered in PDAC is an alteration of codon 12 from glycine to aspartic acid (G12D), which prevents GTP hydrolysis, trapping KRAS in the constitutively active configuration. KRAS activation is coupled to transcription through a number of downstream effectors including the RAF-mitogen activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3K) pathways, ultimately leading to enhanced cellular proliferation, survival, and motility all of which are commonly perturbed in cancer (7, 8) . Similar activating mutations of KRAS and other RAS family members have been implicated in a broad range of human cancers including breast, colon, lymphoma malignancies (9) , highlighting the widespread role for RAS signaling in tumor development and progression.
It is becoming clear that miRNAs have the potential to regulate the majority of protein coding transcripts but how miRNA-mediated regulation is integrated into RAS signaling pathways is still poorly understood. Indeed miRNAs have been found to target RAS genes themselves, including let-7 miRNA, miR-143 and miR-217 which have been experimentally demonstrated to target the KRAS 3'UTR (10, 11, 12) . Recently, miR-21 has been found to be up regulated by oncogenic RAS through the MAPK pathway and the genetic deletion of miR-21 is able to suppress KRAS-driven tumors (13) .
Previously, it has been demonstrated that expression of oncogenic KRAS in a transformed pancreatic ductal epithelial cell line (HPNE) leads to deregulation of four miRNAs (5) . Specifically, greater than two-fold up regulation of miR-34a and miR- 31 
RREB-1.
These results demonstrated a feed-forward mechanism through which KRAS activation suppresses expression of an anti-tumorigenic miRNA cluster and concomitantly potentiated signaling through the RAS pathway.
Although miR-31 was identified in the aforementioned screen as being upregulated by mutant KRAS (5), its role in KRAS-mediated tumorigenesis is currently unknown. In addition, RT-PCR and qPCR: cDNAs were made using the QuantiTect kit following the manufacturer's protocol (Qiagen). QPCR was performed using an ABI7900 system with the Fast-SYBR Green PCR core reagent (Applied Biosystems). Primer sequences are provided in Supplementary (5) . In the present study, the focus is on the KRAS mediated regulation of miR-31 which was upregulated by 2.6 fold in HPNE-KRAS cells ( Figure 1A ). To further validate the correlation between KRAS expression to miR-31 upregulation, the expression of miR-31 was examined in isogenic HCT116 cells in which either the wild-type allele of KRAS or the mutant allele was disrupted by homologous recombination (20) . Using Taqman qPCR, miR-31 expression was reduced in HCT116 cells that lacked the mutant KRAS allele (Supplemental Figure 1A) . In addition, acute knockdown of KRAS RAS proteins signal through multiple effector pathways of which the RAF/MEK/ERK pathway (MAPK) and the PI3K/AKT pathways are required for transformation (7) . To assess whether miR-31 expression was dependent on MAPK and/or PI3K activation, HPNE-KRAS and HCT116 cells were treated with the PI3K inhibitor LY294002 or the MEK1/2 inhibitor UO126. Levels of miR-31 decreased following MEK1/2 inhibition but no change was observed with PI3K inhibition suggesting miR-31 is activated through the MAPK pathway ( Figure 1C ).
Finally, miR-31 expression was analyzed from RNA isolated from a panel of patient derived xenografts, normal pancreas tissue and pancreatic and colorectal cancer cell lines. MiR-31 was moderately to highly expressed in most of the patient derived xenografts ( Figure 1D ). It was observed that 16/23 cell lines have moderate to high expression of miR-31 compared to HPNE which served as the "normal" control ( Figure 1E ). Of note, two cancer cell lines in the panel with wild-type KRAS (BxPc3 and Colo205) showed no expression of miR-31 ( Figure 1E ).
Collectively, these results suggest that miR-31 is a downstream target gene of the KRAS-MAPK pathway and exhibits moderate to high expression in pancreatic tumors as well as pancreatic and colorectal cancer cell lines with oncogenic KRAS.
Confirmation of the miR-31 host gene expression and transcription regulation through ELK1.
MicroRNAs are processed from the introns or exons of primary-miRNA (pri-miRNAs) which may be protein-coding or non-coding transcripts (21, 22) . The mature miR-31 and premiRNA stem loop are contained within an NCBI RNA reference sequence transcript (MIR31HG); a long non-coding RNA that spans over 100 kb (Figures 2A and 2B) . Regions within the lncRNA are highly conserved and the transcription start site (TSS) is found in a region high in histone H3-Lysine27 acetylation (H3K27Ac) a mark indicative of actively transcribed chromatin ( Figure   2A ). To validate MIR31HG as the miR-31 primary transcript, qPCR primers were designed within the first exon of the pri-miRNA and MIR31HG expression was measured from RNA isolated from the panel of pancreatic and colorectal cancer cell lines examined in Figure 1 Figure 2D ). In addition, MIR31HG was found to be 4-fold upregulated in HPNE-KRAS cells relative to expression in HPNE ( Figure 2E To identify the minimal RAS responsive region contained within the HG-3 promoter, the effect of acute KRAS knockdown on luciferase expression driven from HG-7 and HG-9 promoter fragments was queried in Panc-1 cells. HG-7 and HG-9 were designed to include or exclude respectively the two peaks of conservation near the TSS ( Figure 3A ). Luciferase expression driven from the HG-9 promoter was diminished when KRAS was knocked down whereas KRAS knockdown had no effect on luciferase expression produced from HG-7 ( Figure 3D ). This suggested that the HG-9 promoter construct contained a RAS responsive sequence required for KRAS-mediated transactivation. To find potential transcription factors (TFs) that may be regulating HG-9 through KRAS and MAPK signaling, the HG-9 sequence was examined using the ConSite algorithm (http://consite.genereg.net/). ConSite allows for the identification and visualization of conserved TF binding sites within metazoan promoters based on comparative phylogenetic footprinting (23) . With an 85% discovery rate and 12-bit sequence analysis, ConSite predicted many highly conserved TF binding elements in HG-9 recognized by 15 individual TFs (Supplemental Table 2 Figure 4F ). These data suggest that miR-31 enhances RhoA activation which likely promotes increased invasion and migration.
RASA1 is a target of miR-31.
To gain insight into the mechanism through which miR-31 enhanced invasion and migration, predicted targets of miR-31 were examined. Since individual miRNA prediction programs find hundreds of potential targets, the intersection of four online searchable miRNA target prediction programs (miR-Database, miR-Target, PicTar, and Targetscan) was analyzed, revealing 18 predicted targets in common (Supplemental Table 3 ). Of these 18 targets, RASA1 (p120RasGAP) was of particular interest because it functions as a negative regulator of RAS 
pathway activation and modulates invasion-behavior through interaction with p190RhoGAP (24, 25) . Moreover, RASA1 was demonstrated to be a miR-31 target in colorectal and liver cancers (26, 27) . The RASA1 3′ UTR contains one predicted miR-31 binding site which is highly conserved in vertebrates ( Figure 5A ). We validated miR-31 regulation of RASA1 using a luciferase reporter plasmid under regulation by a fragment of the RASA1-3'UTR containing the putative miR-31 binding site. Co-transfection of this reporter with a miR-31 mimic led to significant repression of luciferase expression which was relieved by introducing mutations into the miRNA binding site ( Figure 5B ). RASA1 was downregulated in HPNE-KRAS cells relative to expression in HPNE ( Figure 5C ). We also observed decreased expression of RASA1 in isogenic HCT116-KRAS mutant versus KRAS null cells (Supplemental Figure 5 ). In addition, over expression of miR-31 in BxPc3 and MiaPaCa2 cells reduced endogenous RASA1 expression at both the protein and mRNA level ( Figures 5D and 5E ). Collectively, our results confirm that miR-31 regulates RASA1 in PDAC cells.
RASA1 loss phenocopies miR-31 over expression and its gain inhibits migration.
To establish a genetic interaction between RASA1 and miR-31, we sought to determine Figure 4B) . Future experiments will be necessary to determine the absolute levels of RASA1 required for further RAS activation in the cell lines harboring oncogenic KRAS.
Finally, to complement our RASA1 knockdown studies, we overexpressed RASA1 in Panc-1 cells which express miR-31 and moderate levels of RASA1. Panc-1 cells were transiently transfected with a plasmid that expressed flag-tagged RASA1 lacking the endogenous 3'UTR (CMV-RASA1) and expression was confirmed by western blot (Supplemental Figure 6B) . Table 3 and references therein). On one hand , miR-31 is found up regulated and to enhance invasion migration in 6 cancer types (cervical, colorectal, cutaneous squamous cell, esophageal squamous cell, Kaposi's sarcoma, lung) and on the other hand, is found down regulated and to repress invasion migration in 7 cancer types (breast, esophageal, Ewing sarcoma, glioma, melanoma, ovarian, prostate). A previous report of the role of miR-31 in pancreatic cancer is ambiguous; both inhibition and enforced expression of miR-31 reduced migration and invasion in PDAC cell lines (35) . In the present study, the Additionally, these data suggest that miR-31 may be a biomarker for highly invasive KRASmutant cancers. 
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